GlassScriptPhysician profile
Lyndee Miller
NPI 1720720253
$1,433.62
in general payments reported to CMS, 2019-2025
24 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $186 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $260.34 | 2024-2025 | |
| Pfizer INC. | $153.81 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $127.14 | 2024-2025 | |
| Novo Nordisk INC | $107.75 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $92.41 | 2025 | Vyepti, Rexulti |
| Amgen INC. | $86.15 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $73.83 | 2025 | Airsupra, Breztri, Farxiga |
| Radius Health, INC. | $65.74 | 2024-2025 | Tymlos |
| Aimmune Therapeutics, INC. | $65.10 | 2024-2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $56.01 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.88 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $40.74 | 2025 | |
| Boston Scientific Corporation | $36.84 | 2025 | Accolade Sr |
| Lilly USA, LLC | $33.92 | 2025 | Jardiance, Mounjaro, Zepbound |
| Viatris Specialty LLC | $24.69 | 2025 | Yupelri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $23.81 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $20.17 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.62 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $17.23 | 2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $16.59 | 2024 | Quviviq |
| Kyowa Kirin, INC. | $15.79 | 2025 | |
| Merck Sharp & Dohme LLC | $15.64 | 2025 | Capvaxive |
| Baxter Healthcare | $14.72 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Dexcom, INC. | $14.70 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyndee Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.